β-cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in NOD mice.
about
Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunityRNase L contributes to experimentally induced type 1 diabetes onset in mice.Identification and Validation of Small Molecules That Enhance Recombinant Adeno-associated Virus Transduction following High-Throughput Screens.Anti-coreceptor therapy drives selective T cell egress by suppressing inflammation-dependent chemotactic cues.Expression of IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabetes through activation of FoxP3-positive regulatory T cells.Gene therapy with an AAV vector expressing human IL-2 alters immune system homeostasis in humanized mice.β-cell-specific IL-35 therapy suppresses ongoing autoimmune diabetes in NOD mice.The contribution of interleukin-2 to effective wound healing.Temporal increase in thymocyte negative selection parallels enhanced thymic SIRPα+ DC function.LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes.Unique Features of Pancreatic-Resident Regulatory T Cells in Autoimmune Type 1 Diabetes.T Cell-Mediated Beta Cell Destruction: Autoimmunity and Alloimmunity in the Context of Type 1 Diabetes.Self-Transducible Bimodal PDX1-FOXP3 Protein Lifts Insulin Secretion and Curbs Autoimmunity, Boosting Tregs in Type 1 Diabetic Mice.Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes
P2860
Q27008200-2A4004FB-6561-497F-A55F-8D4FC391DB70Q34475565-E03F85F5-DD90-4562-8CE1-D9BC2F868F63Q36009041-63A7BE62-620D-41C2-963F-2CD406B3BE19Q37351576-A10ADB50-D816-48D1-B56C-E20122507B5CQ38449217-3EDB972D-8344-483B-A21A-E7A2B4DB2082Q38616032-1A79DC5B-9DB9-4939-A21C-DF38C61BC5BBQ38730525-6AED0603-4F7A-4CCB-8D92-74CEEA71B889Q38995167-E42235A3-1308-4F81-B16F-F2ECAFAD0FD0Q41641071-FCE9F126-69BE-4E78-860A-D40D2888DF57Q41703479-83010861-D7EF-43B0-AFC9-3884453B7673Q42369832-E0B8715D-5775-49D5-8722-2DE801C2756BQ47093542-E01B9D92-7935-4CC8-A1D5-D7282FA8DC01Q47681040-4B688B70-9437-4580-8621-E65E7186BBF4Q58773667-ABC99B5A-1CA5-4776-B376-21595504F7FA
P2860
β-cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in NOD mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
β-cell-specific IL-2 therapy i ...... s type 1 diabetes in NOD mice.
@en
β-cell-specific IL-2 therapy i ...... s type 1 diabetes in NOD mice.
@nl
type
label
β-cell-specific IL-2 therapy i ...... s type 1 diabetes in NOD mice.
@en
β-cell-specific IL-2 therapy i ...... s type 1 diabetes in NOD mice.
@nl
prefLabel
β-cell-specific IL-2 therapy i ...... s type 1 diabetes in NOD mice.
@en
β-cell-specific IL-2 therapy i ...... s type 1 diabetes in NOD mice.
@nl
P2093
P2860
P356
P1433
P1476
β-cell-specific IL-2 therapy i ...... s type 1 diabetes in NOD mice.
@en
P2093
Alaina L Garland
Chengwen Li
Mark C Johnson
R Jude Samulski
Roland Tisch
Sarah C Nicolson
P2860
P304
P356
10.2337/DB13-0669
P407
P577
2013-07-24T00:00:00Z